Twist Bioscience Q3 FY2024 revenue $81.5M (+28% YoY); raises FY2024 guidance to ~$310-311M

Twist Bioscience Corp

2024-Q3 EPS reported -$3.01 revenue$228,264,000

Revenue $81.5M, up 28% YoY; gross margin 43.3%, up ~900 bps from 34.4%.
Net loss GAAP $85.6M ($1.47/sh) includes $45M Biopharma impairment; adjusted net loss $40.6M.
Adjusted EBITDA improved to $(22.0)M from $(29.6)M YoY; orders grew to $85.3M.
FY2024 revenue guidance raised to ~$310-311M; gross margin guidance ~42% (high end).
SynBio revenue $33.0M, NGS $43.4M, Biopharma $5.1M; cash $289.4M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.